October 10, 2017 09:21 AM EDTUpdated 10:32 AM
News Briefing

Am­gen catch­es a break as FDA re­jects Neu­las­ta knock­off; Zaf­gen gets a new CEO as Hugh­es moves to top sci­ence job

Shehla Shakoor

Managing Director

→ Am­gen caught a break to­day on its block­buster fran­chise drug Neu­las­ta. The FDA has re­ject­ed an ap­pli­ca­tion from Bio­con and My­lan for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times